Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.